Acrivon CEO may sell 41,167 shares of company stock

Acrivon Therapeutics, Inc. (ACRV) received a notice under Rule 144 relating to potential sales of its common stock by President and CEO Dr. Peter Blume-Jensen.

Rhea-AI Filing Summary

Acrivon Therapeutics, Inc. (ACRV) received a notice under Rule 144 relating to potential sales of its common stock by President and CEO Dr. Peter Blume-Jensen. The notice lists 41,167 shares of common stock to be sold upon settlement on 08/21/2026, arising from vested RSUs issued under an S-8 equity compensation plan, with the issuer shown as the source and the purpose described as equity compensation for services rendered.

The filing also reports that in the prior three months, automatic sales were made solely to cover mandatory tax withholding on RSU vesting: on 08/18/2026, Dr. Blume-Jensen sold 1,229 shares for proceeds of $2,470.29, and his spouse, director and officer Dr. Kristina Masson, sold 484 shares for proceeds of $972.84. The shares to be sold are held through Morgan Stanley Smith Barney LLC Executive Services, with a listed market on NASDAQ.

Key Figures

Shares to be sold: 41,167 shares of common stock CEO shares sold in past 3 months: 1,229 shares for $2,470.29 Spouse shares sold in past 3 months: 484 shares for $972.84 +2 more

5 metrics

Shares to be sold 41,167 shares of common stock Settlement of vested RSUs on 08/21/2026 as equity compensation

CEO shares sold in past 3 months 1,229 shares for $2,470.29 Automatic sale on 08/18/2026 to satisfy tax withholding

Spouse shares sold in past 3 months 484 shares for $972.84 Automatic sale on 08/18/2026 to satisfy tax withholding

Rule 144 notice date 08/25/2026 Date of notice for planned sales of ACRV common stock

Broker Morgan Stanley Smith Barney LLC Executive Services Listed as the broker for the common stock covered by the notice

Key Terms

Rule 144, restricted stock units, S-8 Registration Plan, equity compensation

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

restricted stock units financial

"Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

S-8 Registration Plan regulatory

"Settlement of vested RSUs issued under an S-8 Registration Plan"

equity compensation financial

"Equity compensation for services rendered"

Equity compensation is pay given to employees, executives or contractors in the form of company ownership—such as stock, stock options or restricted shares—rather than just cash. It matters to investors because it can align workers' incentives with shareholders (like paying someone in slices of the same pie they help grow), but it also increases the number of shares outstanding and company expenses, affecting ownership percentages and earnings per share.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for ACRV disclose about planned stock sales?

The notice states that Acrivon’s President and CEO, Dr. Peter Blume-Jensen, may sell 41,167 shares of common stock on or about 08/21/2026. These shares arise from vested RSUs under an S-8 equity compensation plan and are characterized as equity compensation for services rendered.

How many ACRV shares were sold in the last three months by the CEO and his spouse?

The filing reports that on 08/18/2026 Dr. Peter Blume-Jensen sold 1,229 shares for $2,470.29, and Dr. Kristina Masson sold 484 shares for $972.84. The remarks state these sales were made automatically to satisfy mandatory tax withholding on RSU vesting.

Who is the person subject to the ACRV Rule 144 notice and what is their role?

The person for whose account securities are to be sold is Dr. Peter Blume-Jensen, identified in the remarks as the President and CEO of Acrivon Therapeutics, Inc. The notice also references his spouse, Dr. Kristina Masson, a director and officer of the issuer.

What is the nature of the ACRV securities covered by the Rule 144 notice?

The securities are common stock of Acrivon Therapeutics, Inc., to be issued upon settlement of vested RSUs under an S-8 Registration Plan. The form specifies that the issuer is the source and describes the transaction as equity compensation for services rendered.

What explanation is given for recent ACRV stock sales by insiders?

The remarks explain that shares were sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. These sales involved the issuer’s President and CEO, Dr. Peter Blume-Jensen, and his spouse, director and officer Dr. Kristina Masson.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/25/2026 - 08:40 PM EDT Accepted by SEC EDGAR 08/25/2026 - 08:40 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001950499
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Acrivon Therapeutics, Inc.
SEC File Number	001-41551
Address of Issuer	480 Arsenal Way Suite 100 Watertown MASSACHUSETTS 02472
Phone	617-207-8979
Name of Person for Whose Account the Securities are To Be Sold	Peter Blume-Jensen
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC Executive Services 200 W Civic Center Drive, 4th Floor Sandy UT 84070	14036	30598.48	42853362	08/25/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	08/21/2026	Settlement of vested RSUs issued under an S-8 Registration Plan	Issuer			41167	08/21/2026	Equity compensation for services rendered

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Peter Blume-Jensen 480 Arsenal Way Suite 100 Watertown MA 02472	Common Stock	08/18/2026	1229	2470.29
Kristina Masson 480 Arsenal Way Suite 100 Watertown MA 02472	Common Stock	08/18/2026	484	972.84

144: Remarks and Signature

Remarks	Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. These securities were sold by the Issuer's President and CEO, Dr. Peter Blume-Jensen. The table of securities sold during the past 3 months includes sales by each of Dr. Peter Blume-Jensen and his spouse, Dr. Kristina Masson, who is also a director and officer of the Issuer.
Date of Notice	08/25/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Adam D. Levy, Attorney-in-Fact
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)